Advertisement

AAPS PharmSciTech

, 20:281 | Cite as

An in vitro Assessment of Thermo-Reversible Gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration

  • Priyanka Bhatt
  • Priya Narvekar
  • Rohan Lalani
  • Mahavir Bhupal Chougule
  • Yashwant Pathak
  • Vijaykumar SutariyaEmail author
Research Article Theme: Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems
Part of the following topical collections:
  1. Theme: Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems

Abstract

Anti-vascular endothelial growth factor agents have been widely used to treat several eye diseases including age-related macular degeneration (AMD). An approach to maximize the local concentration of drug at the target site and minimize systemic exposure is to be sought. Sunitinib malate, a multiple receptor tyrosine kinase inhibitor was encapsulated in poly(lactic-co-glycolic acid) nanoparticles to impart sustained release. The residence time in vitreal fluid was further increased by incorporating nanoparticles in thermo-reversible gel. Nanoparticles were characterized using TEM, DSC, FTIR, and in vitro drug release profile. The cytotoxicity of the formulation was assessed on ARPE-19 cells using the MTT assay. The cellular uptake, wound scratch assay, and VEGF expression levels were determined in in vitro settings. The optimized formulation had a particle size of 164.5 nm and zeta potential of − 18.27 mV. The entrapment efficiency of 72.0% ± 3.5% and percent drug loading of 9.1 ± 0.7% were achieved. The viability of ARPE-19 cells was greater than 90% for gel loaded, as such and blank nanoparticles at 10 μM and 20 μM concentration tested, whereas for drug solution viability was found to be 83% and 71% respectively at above concentration. The cell viability results suggest the compatibility of the developed formulation. Evaluation of cellular uptake, wound scratch assay, and VEGF expression levels for the developed formulations indicated that the formulation had higher uptake, superior anti-angiogenic potential, and prolonged inhibition of VEGF activity compared with drug solution. The results showed successful development of sunitinib-loaded nanoparticle-based thermo-reversible gel which may be used for the treatment of neovascular AMD.

KEY WORDS

sunitinib PLGA nanoparticles sustained release ocular delivery intravitreal VEGF 

Notes

Acknowledgments

The authors would like to acknowledge the Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, USA, for providing start-up support to Dr. Chougule’s lab. The authors would also like to acknowledge the Lisa Muma Weitz Laboratory for Advanced Microscopy and Cell Imaging, USF Health, University of South Florida, Tampa, FL, USA, for providing facility for microscopy and imaging and Department of Chemistry, College of Arts and Science, University of South Florida, Tampa, FL, USA, for providing facility for DSC study.

Funding Information

The authors would like to thank High Tech Corridor Matching Grant Program (FHT 17-20) with Param Bhakti Healthcare and Research for providing necessary funding for this work.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

12249_2019_1474_MOESM1_ESM.docx (14 kb)
ESM 1 (DOCX 13 kb)

References

  1. 1.
    Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vision. 2016;3(1):34.PubMedGoogle Scholar
  2. 2.
    Shang Q, Zhai J, Tian R, Zheng T, Zhang X, Liang X, et al. Fabrication, characterization, and controlled release of eprinomectin from injectable mesoporous PLGA microspheres. RSC Adv. 2015;5(92):75025–32.Google Scholar
  3. 3.
    Hoare TR, Kohane DS. Hydrogels in drug delivery: progress and challenges. Polymer. 2008;49(8):1993–2007.Google Scholar
  4. 4.
    Chou R, Dana T, Bougatsos C, Grusing S, Blazina I. Screening for impaired visual acuity in older adults: updated evidence report and systematic review for the US Preventive Services Task Force. Jama. 2016;315(9):915–33.PubMedGoogle Scholar
  5. 5.
    Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58(3):353.PubMedGoogle Scholar
  6. 6.
    Al Gwairi O, Thach L, Zheng W, Osman N, Little PJ Cellular and molecular pathology of age-related macular degeneration: potential role for proteoglycans. J Ophthalmol 2016;2016, 1–7.  https://doi.org/10.1155/2016/2913612 Google Scholar
  7. 7.
    Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358(24):2606–17.PubMedGoogle Scholar
  8. 8.
    Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res. 2010;29(2):144–68.PubMedGoogle Scholar
  9. 9.
    Pożarowska D, Pożarowski P. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol. 2016;41(3):311.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser. Available from: https://ClinicalTrials.gov/show/NCT03590444. Accessed 23 May 2018.
  11. 11.
    Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR). Available from: https://ClinicalTrials.gov/show/NCT03452657. Accessed 23 May 2018.
  12. 12.
    Maguire MG, Martin DF, Ying G-S, Jaffe GJ, Daniel E, Grunwald JE, et al. Five-year outcomes with anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–61.PubMedGoogle Scholar
  13. 13.
    Pieramici DJ, Lu N, Stoilov IJIO, Science V. Diabetic retinopathy outcomes with anti-VEGF treatments: clinical experience in randomized clinical trials. 2015;56(7):1775.Google Scholar
  14. 14.
    Schwartz SG, Scott IU, Flynn HW Jr, Stewart MW. Drug delivery techniques for treating age-related macular degeneration. Expert Opin Drug Deliv. 2014;11(1):61–8.PubMedGoogle Scholar
  15. 15.
    Del Amo EM, Rimpelä A-K, Heikkinen E, Kari OK, Ramsay E, Lajunen T, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134–85.PubMedGoogle Scholar
  16. 16.
    Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review. Clin Interv Aging. 2017;12:1313–30.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Le Tourneau C, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag. 2007;3(2):341.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Mena AC, Pulido EG, Guillen-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anti-Cancer Drugs. 2010;21:S3–S11.PubMedGoogle Scholar
  19. 19.
    Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377–97.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J, et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomed Nanotechnol Biol Med. 2010;6(5):662–71.Google Scholar
  21. 21.
    Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J Microencapsul. 2018;35(2):204–17.PubMedGoogle Scholar
  22. 22.
    Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: enhanced loading efficiency and its pharmacokinetic evaluation. Int J Pharm. 2018;536(1):95–107.PubMedGoogle Scholar
  23. 23.
    Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, et al. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. J Drug Delivery Sci Technol. 2018;45:334–45.Google Scholar
  24. 24.
    Patil S, Bhatt P, Lalani R, Amrutiya J, Vhora I, Kolte A, et al. Low molecular weight chitosan–protamine conjugate for siRNA delivery with enhanced stability and transfection efficiency. RSC Adv. 2016;6(112):110951–63.Google Scholar
  25. 25.
    Hirani A, Grover A, Lee YW, Pathak Y, Sutariya V. Triamcinolone acetonide nanoparticles incorporated in thermoreversible gels for age-related macular degeneration. Pharm Dev Technol. 2016;21(1):61–7.PubMedGoogle Scholar
  26. 26.
    Zhang C, Qineng P, Zhang H. Self-assembly and characterization of paclitaxel-loaded N-octyl-O-sulfate chitosan micellar system. Colloids Surf B: Biointerfaces. 2004;39(1–2):69–75.PubMedGoogle Scholar
  27. 27.
    Bhatt P, Khatri N, Kumar M, Baradia D, Misra A. Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer. Drug Deliv. 2015;22(6):849–61.PubMedGoogle Scholar
  28. 28.
    Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved <em>in vitro</em> efficacy on ovarian cancer cells. Cancer Research. 2016;76(14 Supplement):2065.Google Scholar
  29. 29.
    Espana-Serrano L, Chougule MB. Enhanced anticancer activity of PF-04691502, a dual PI3K/mTOR inhibitor, in combination with VEGF siRNA against non-small-cell lung cancer. Mol Ther Nucleic Acids. 2016;5(11):e384.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Goel PN, Gude RP. Unravelling the antimetastatic potential of pentoxifylline, a methylxanthine derivative in human MDA-MB-231 breast cancer cells. Mol Cell Biochem. 2011;358(1–2):141–51.PubMedGoogle Scholar
  31. 31.
    Kim KL, Suh W. Apatinib, an inhibitor of vascular endothelial growth factor receptor 2, suppresses pathologic ocular neovascularization in mice. Invest Ophthalmol Vis Sci. 2017;58(9):3592–9.PubMedGoogle Scholar
  32. 32.
    Kathleen H, Shannon JK, Iqbal MT, Yashwant P, Vijaykumar S. Utilization of apatinib-loaded nanoparticles for the treatment of ocular neovascularization. Curr Drug Deliv. 2019;16(2):153–63.Google Scholar
  33. 33.
    Pirooznia N, Hasannia S, Lotfi AS, Ghanei M. Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles: in vitro characterization as an effective aerosol formulation in pulmonary diseases. J Nanobiotechnol. 2012;10:20.Google Scholar
  34. 34.
    Singh R, Kesharwani P, Mehra NK, Singh S, Banerjee S, Jain NK. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity. Drug Dev Ind Pharm. 2015;41(11):1888–901.PubMedGoogle Scholar
  35. 35.
    Kovach JL, Schwartz SG, Flynn HW, Scott IU. Anti-VEGF treatment strategies for wet AMD. J Ophthalmol. 2012;2012:786870.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One. 2008;3(11):e3554.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti–vascular endothelial growth factor therapy in medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152(2):266–72.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman ASJO. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112(6):1035–47. e9.PubMedGoogle Scholar
  39. 39.
    Sharma S, Johnson D, Abouammoh M, Hollands S, Brissette A. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol. 2012;47(3):275–9.PubMedGoogle Scholar
  40. 40.
    Medina C, Santos-Martinez M, Radomski A, Corrigan O, Radomski MJB. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol. 2007;150(5):552–8.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26(5):1197.PubMedGoogle Scholar
  42. 42.
    Stevenson CL, Santini JT Jr, Langer R. Reservoir-based drug delivery systems utilizing microtechnology. Adv Drug Deliv Rev. 2012;64(14):1590–602.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Alshetaili AS, Anwer MK, Alshahrani SM, Alalaiwe A, Alsulays BB, Ansari MJ, et al. Characteristics and anticancer properties of sunitinib malate-loaded poly-lactic-co-glycolic acid nanoparticles against human colon cancer HT-29 cells lines. Tropical Journal of Pharmaceutical Research. 2018;17(7):1263−9.Google Scholar
  44. 44.
    Sadat SM, Jahan ST, Haddadi AJ. Effects of size and surface charge of polymeric nanoparticles on in vitro and in vivo applications. Nanobiotechnology. 2016;7(02):91.Google Scholar
  45. 45.
    Tandel H, Bhatt P, Jain K, Shahiwala A, Misra A. Chapter-1: In-vitro and in-vivo tools in emerging drug delivery scenario: Challenges and Updates. In-vitro and In-vivo tools in drug delivery research for optimum clinical outcomes; 2018; 1st edition; Editors: Misra A and Shahiwala A. CRC press, Boca Raton. 8–1.  https://doi.org/10.1201/b2244.
  46. 46.
    Huo M, Zhao Y, Satterlee AB, Wang Y, Xu Y, Huang LJ. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release. 2017;245:81–94.PubMedGoogle Scholar
  47. 47.
    Ambasta RK, Sharma A, Kumar PJ. Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vasc Cell. 2011;3(1):26.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Senger DR, Davis GE. Cold Spring Harbor perspectives in biology. Angiogenesis. n.d.;3(8):a005090-a.Google Scholar
  49. 49.
    Hulkower KI, Herber RL. Cell migration and invasion assays as tools for drug discovery. Pharmaceutics. 2011;3(1):107–24.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Carmeliet PJO. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69(Suppl. 3):4–10.PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • Priyanka Bhatt
    • 1
  • Priya Narvekar
    • 1
  • Rohan Lalani
    • 2
  • Mahavir Bhupal Chougule
    • 3
  • Yashwant Pathak
    • 1
    • 4
  • Vijaykumar Sutariya
    • 1
    Email author
  1. 1.Department of Pharmaceutical SciencesUniversity of South FloridaTampaUSA
  2. 2.Faculty of PharmacyThe Maharaja Sayajirao University of BarodaVadodaraIndia
  3. 3.School of PharmacyUniversity of MississippiOxfordUSA
  4. 4.Faculty of PharmacyAirlangga UniversitySurabayaIndonesia

Personalised recommendations